Welcome to our dedicated page for Catalyst Pharmaceuticals news (Ticker: CPRX), a resource for investors and traders seeking the latest updates and insights on Catalyst Pharmaceuticals stock.
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The CPRX news feed on Stock Titan aggregates company announcements, financial updates, scientific disclosures, and investor conference appearances drawn from Catalyst’s own public communications and regulatory filings.
Readers can find earnings and financial result announcements, where Catalyst reports product revenue contributions from FIRDAPSE, AGAMREE, and FYCOMPA, along with commentary on operating performance and business outlook. These releases often discuss factors such as organic growth in Lambert-Eaton myasthenic syndrome markets, demand in Duchenne muscular dystrophy centers of excellence, and the impact of generic competition on specific products.
The news stream also features corporate and strategic updates, including authorization of share repurchase programs, patent litigation settlements related to FIRDAPSE, and developments in clinical practice guidelines that reference conditions and therapies linked to the company’s portfolio. In addition, Catalyst regularly announces participation in major healthcare and investor conferences, providing insight into how management presents the story behind CPRX to the investment community.
For those following the scientific and patient-focused side of the business, the news includes conference presentations and advocacy initiatives, such as real-world analyses in Duchenne muscular dystrophy, research on Lambert-Eaton myasthenic syndrome, and programs like the Catalyst Advocacy Scholars Summit with academic partners. Investors, analysts, and patients can use this page to monitor how Catalyst’s rare disease strategy, clinical activities, and capital allocation decisions evolve over time. Bookmark this CPRX news page for a centralized view of the company’s key public announcements.
Catalyst Pharmaceuticals (Nasdaq: CPRX) announced several leadership promotions, including Jeffrey Del Carmen to Chief Commercial Officer. Del Carmen, who previously served as Senior Vice President of Sales and Marketing, will lead efforts to expand access to the company's Firdapse product for Lambert-Eaton myasthenic syndrome (LEMS) and prepare for a potential launch for anti-MuSK antibody positive myasthenia gravis. The company also promoted Pete Curry to Vice President of Sales and Maria Pandolfo to Vice President of Patient Services.
Catalyst Pharmaceuticals, focused on rare neuromuscular diseases, announced its presentation at the Jefferies Virtual Healthcare Conference on June 2-4, 2020. CEO Patrick J. McEnany and CSO Steven Miller will host one-on-one investor meetings, with their presentation on June 4 at 8:30 a.m. E.T. The event will be accessible via the company's investor webpage. Catalyst's Firdapse® (amifampridine) is FDA-approved for Lambert-Eaton myasthenic syndrome and is under evaluation for other conditions. The press release emphasizes Catalyst's commitment to innovative therapies.
Catalyst Pharmaceuticals (Nasdaq: CPRX) reported Q1 2020 net revenues of $29.1 million, a 134% increase from the previous year. The company achieved a GAAP net income of $10.4 million or $0.10 per share, compared to a loss of $645,000 in Q1 2019. Catalyst withdrew its 2020 revenue guidance due to COVID-19 uncertainties while highlighting minimal impact on Q1 revenues. The firm ended the quarter with $101.8 million in cash and no debt and expanded its sales force to enhance the Firdapse franchise. Upcoming milestones include Phase 3 trial results for MuSK-MG expected in Q3 2020.
Summary not available.